诺和诺德新减肥药在华临床试验申请获受理，效果或优于司美格鲁肽

澎湃新闻04-10

在业内还在期待GLP-1药物司美格鲁肽注射液在中国获批减重适应证之时，诺和诺德在中国的减重布局再落一子。4月10日，中国国家药监局药品审评中心(CDE)官网公示，诺和诺德1类新药Amycretin片的临床试验申请获得受理，药品类型为治疗用生物制品。CDE公示诺和诺德药品获受理根据诺和诺德2023年年报，Amycretin是一款口服GLP-1受体和胰淀素受体的长效联合激动剂，处于一期临床研究阶段，在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2426349688?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-10 20:51","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2426349688","market":"us","top_or_hot":-1,"title":"诺和诺德新减肥药在华临床试验申请获受理，效果或优于司美格鲁肽","media":"澎湃新闻","content":"<div>\n<p>在业内还在期待GLP-1药物司美格鲁肽注射液在中国获批减重适应证之时，诺和诺德在中国的减重布局再落一子。4月10日，中国国家药监局药品审评中心(CDE)官网公示，诺和诺德1类新药Amycretin片的临床试验申请获得受理，药品类型为治疗用生物制品。CDE公示诺和诺德药品获受理根据诺和诺德2023年年报，Amycretin是一款口服GLP-1受体和胰淀素受体的长效联合激动剂，处于一期临床研究阶段，在...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102052288b0a3b9c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德新减肥药在华临床试验申请获受理，效果或优于司美格鲁肽</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德新减肥药在华临床试验申请获受理，效果或优于司美格鲁肽\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-10 20:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102052288b0a3b9c&s=b><strong>澎湃新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>在业内还在期待GLP-1药物司美格鲁肽注射液在中国获批减重适应证之时，诺和诺德在中国的减重布局再落一子。4月10日，中国国家药监局药品审评中心(CDE)官网公示，诺和诺德1类新药Amycretin片的临床试验申请获得受理，药品类型为治疗用生物制品。CDE公示诺和诺德药品获受理根据诺和诺德2023年年报，Amycretin是一款口服GLP-1受体和胰淀素受体的长效联合激动剂，处于一期临床研究阶段，在...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102052288b0a3b9c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102052288b0a3b9c&s=b","article_id":"2426349688","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102052288b0a3b9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2426349688","pubTimestamp":1712753460,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"4月10日，中国国家药监局药品审评中心官网公示，诺和诺德1类新药Amycretin片的临床试验申请获得受理，药品类型为治疗用生物制品。以此推测，诺和诺德在中国递交临床试验申请的是也极有可能是Amycretin的口服版本，不过这一信息并未有官方证实。诺和诺德2023年财报显示，减肥版司美格鲁肽Wegovy销售额暴涨406%达到46亿美元，在全球GLP-1赛道遥遥领先。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4532":"文艺复兴科技持仓","NVO":"诺和诺德","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4007":"制药"},"translate_title":"Novo Nordisk's new weight-loss drug application for clinical trials in China has been accepted, and the effect may be better than semaglutide","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"在业内还在期待GLP-1药物司美格鲁肽注射液在中国获批减重适应证之时，诺和诺德在中国的减重布局再落一子。4月10日，中国国家药监局药品审评中心(CDE)官网公示，诺和诺德1类新药Amycretin片的临床试验申请获得受理，药品类型为治疗用生物制品。CDE公示诺和诺德药品获受理根据诺和诺德2023年年报，Amycretin是一款口服GLP-1受体和胰淀素受体的长效联合激动剂，处于一期临床研究阶段，在研适应证为肥胖，每周一次皮下治疗或每天一次口服治疗，其中口服Amycretin的一期临床试验成功完成。以此推测，诺和诺德在中国递交临床试验申请的是也极有可能是Amycretin的口服版本，不过这一信息并未有官方证实。诺和诺德的减肥管线 来源：2023年财报诺和诺德旗下的王牌减重药品是司美格鲁肽，注射剂型或将于今年年内在中国获批用于减重。根据此前公布的试验数据，在持续68周的试验期间，司美格鲁肽注射液组的体重降低14.9%，12周时体重降低6%。相比之下，口服Amycretin的肥胖患者在12周后体重减轻了约13.1%。作为GLP-1药物的代表，司美格鲁肽在商业上取得成功。诺和诺德2023年财报显示，减肥版司美格鲁肽Wegovy销售额暴涨406%达到46亿美元，在全球GLP-1赛道遥遥领先。不考虑入组情况、使用剂量等因素，Amycretin的减重效果以及口服的便利性均优于司美格鲁肽注射液。据公开报道，今年3月，诺和诺德首席执行官Lars Rebien Sorensen也曾公开表示，这款在研减肥药有可能成为治疗肥胖症的同类最佳药物。需要注意的是，这款似乎更强大的减重药物想要真正为减重患者所用，仍需要几年的时间。根据当时公布的消息，Amycretin的中期试验将于今年下半年开始，预计2026年初得出结果。还有诺和诺德高管在接受媒体采访时表示，公司或在这个十年（2020年-2030年）推出Amyctin。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426349688"}